Pakistan Pharma Career Door Newsletter ,Issue 4, Volume 4 by Javeriya Ansari(Pharmacist)

1. The European Medicines
Agency's Committee on
19th May ,2017 ,Medicinal
Products for Human Use
(CHMP) has recommended
granting marketing
authorization
for Trimbow (Chiesi Far-
maceutici S.p.A., Italy), a
combination of three
inhaled medications, for
the maintenance treatment
of adults with moderate to
severe chronic obstructive
pulmonary disease (COPD)
who do not respond
adequately to a
combination of an inhaled
corticosteroid and a long-
acting β2-agonist.
Trimbow
(beclometasone
dipropionate/formoterol
fumarate dihydrate/
glycopyrronium
bromide) is an inhaled
formulation containing a
glucocorticoid, a long-
acting β2 receptor agonist,
and a long-acting mus-
carinic antagonist, respec-
tively.
Beclometasone reduces
lung inflammation,
whereas formoterol and
glycopyrronium relax
bronchial smooth muscle
and dilate the airways.
The triple-drug combina-
tion will be formulated as
a pressurized metered-
dose inhaler that admin-
isters a solution with a
nominal dose per
actuation of 87 μg/5 μg/9
μg of the active sub-
stances, respectively.
The inhaled combination
relieves and prevents
symptoms, including
shortness of breath,
wheezing, and cough, and
reduces flare-ups of
COPD symptoms.
Volume 4, Issue 4
10th JULY, 2017
WEEKLY PHARMA NEWSLETTER
It is unfortunate that despite
immense potential our phar-
maceutical industry is still
behind India and Bangladesh
in exports.
The reasons obviously are
poor drug regulations,
uncompromising attitude of
DRAP and Pakistan’s inability
to secure quality certification
from international agencies.
Our drug manufacturers are
not allowed third-party con-
tracts — a facility which gives
India and Bangladesh a clear
edge over Pakistan. It is time
the current legislation which
restricts contract mfg. of
medicines for export be
revised.
Third-party manufacturing
would bring in foreign invest-
ment as international drug
manufacturers would prefer to
outsource medicine produc-
tion to Pakistani firms to off-
set their own high-prod. costs.
CHMP Recommends Triple Combo for
COPD Maintenance
Allowing Paki - Drug Manufacturers for Third-party
Contract Manufacturing Would Bring Foreign Investment.
PAKISTAN PHARMA CAREER DOOR
NEWSLETTER
CHMP Recommends
Triple Combo for COPD
Maintenance
1
Allowing Paki—Drug Manu-
facturers for Third-party
Contract Manufacturing
Would Bring Foreign Invest-
ment.
1
New Drug Approvals 2
New Discoveries 3
Pharma News 4
Classified 5
Info about Pakistan
Pharma Career Door
6
Useful App. 6
Inside this issue:
BY DR.JAVERIYA ANSARI ( PHARMACIST)

2. * On 7th July, 2017 U.S. Food and
Drug Administration approved
Endari (L-glutamine oral pow-
der) for patients age five years and
older with sickle cell disease (an
inherited blood disorder in which
the red blood cells are abnormally
shaped (in a crescent, or "sickle,"
shape) to reduce severe complica-
tions associated with the blood
disorder.
Endari is the first treatment
approved for patients with sickle
cell disease in almost 20 years,"
said Richard Pazdur, M.D., acting
director of the Office of Hematology
and Oncology Products in the FDA’s
Center for Drug Evaluation and
*On 5th July,2017 FDA grants the
tentative approval for the
conversion of status of
Omeprazole 20mg from partial
Prescription Drug to Over the
counter (OTC) medicine .
The FDA granted the approval of
Omeprazole to Dexcel Pharma .
P A G E 2
Research and director of the FDA’s
Oncology Center of Excellence .
Endari received Orphan Drug
designation for this use, which pro-
vides incentives to assist and en-
courage the
development
of drugs for
rare diseases.
The FDA
granted the
approval of Endari to Emmaus
Medical Inc.
and severity of hair loss during
chemotherapy in solid tumor cancer
patients in which alopecia-inducing
chemotherapeutic agents and doses
are used. It is a computer-
controlled system used during
treatment. A cap is worn on the
head and circulates liquid to a cap
to cool the scalp during chemother-
apy treatment. The cap is covered
by a second cap made from neo-
prene, a type of rubber that holds
the cooling cap in place and acts as
an insulation cover to prevent loss
of cooling and low temperature
these combined actions are thought
to reduce the effect chemotherapy
has on the cells, which may reduce
hair loss.
The cooling is intended to constrict
blood vessels in the scalp, that re-
duces chemo rays that reaches cells
in the hair follicles.
03 July 2017, the U.S. Food and
Drug Administration cleared the
expanded use of a cooling cap,
DigniCap Cooling System to
Dignitana Inc., to reduce hair loss
(alopecia) during chemotherapy.
This is the first cooling cap cleared
by the agency for use in cancer pa-
tients with solid tumors.
The DigniCap Cooling System is
indicated to reduce the frequency
P A K I S T A N P H A R M A C A R E E R D O O R
INTERESTING INFORMATION :
FDA clears expanded use of cooling cap to reduce hair loss during chemotherapy
NEW DRUG APPROVALS :

3. This was done because, as previous
assertions likely made clear, doctors
hoped that this would help ―jump-
start‖ his brain back to functional-
ity. And notably, according to
the UCLA Newsroom’s release, the
patient has regained full conscious-
ness and full language comprehen-
sion just after three days.
At this point, the reliability of
Monti’s treatment requires further
study—which means that he needs
to have additional patients in order
to determine whether it could be
used consistently as a treatment for
people who are in a coma.
25-year old man has made
―incredible‖ progress after being the
first person to receive a new UCLA
treatment…one that ―jump-started‖
his brain out of a coma.
The treatment targeted the
thalamus with low-intensity
focused ultrasound pulsation.
– , was led by Martin Monti, a
UCLA associate professor of psy-
chology and neurosurgery.
if the study pans out, the treat-
ment could eventually be used to
build a low-cost, portable device to
help ―wake up‖ patients completely
from their comas.
the number of music therapy sessions
as well as the quality of the therapy.
"Moderate- to low-quality evidence
suggests that music therapy as an
addition to standard care improves
the global state, mental state
(including negative and general
symptoms), social functioning, and
quality of life of people with schizo-
phrenia or schizophrenia-like disor-
ders," the investigators, led by
Music Therapy May Strike the
Right Note for Schizophrenia:
Music therapy may provide some-
thing drugs or other treatments don't
for patients with schizophrenia,
results of a new Cochrane Re-
view article show.
However, the effects were inconsis-
tent across studies and depended on
Monika Geretsegger, PhD, the Grieg
Academy Music Therapy Research
Centre, Uni Research Health, Bergen,
Norway
P A G E 3
NEW DISCOVERIES :
NEW DISCOVERIES :
for myocarditis, which can occur
when the heart becomes infected by
a common virus, and leads to heart
failure in around 30 percent of
cases. Myocarditis causes chemicals
called chemokines to be released in
the heart, which in turn attracts
cells leading to inflammation in the
organ, and it's these chemokines
that tick spit can help to neutralise.
"With this research, we hope to be
able to take inspiration from the
tick's anti-inflammatory strategy
and design a life-saving therapy for
this dangerous heart condition and
other diseases stroke, pancreatitis,
and arthritis."
Proteins Found in Tick Spit
Could Save You From Heart
Disease :
Saliva from ticks could be a poten-
tial lifesaver, scientists have discov-
ered, as it's been shown to block the
harmful chemicals associated with a
particular kind of heart disease.
If we can develop a drug from this
tick spit as treatment option
V O L U M E 4 , I S S U E 4
“The only way to discover the limits of
possible is to go beyond them into the
impossible .”
~SIR ARTHUR CLARKE .
NEW DISCOVERIES :

4. Below are three new classes of
Diabetes drugs(June 30, 2017),
their clinical usefulness, and certain
subsets of patients in whom they
should be avoided.
Incretin Drugs :
*GLP-1 Receptor Agonists
The glucagon-like peptide-1 (GLP-1)
agonists are divided into short-
acting and long-acting agents.
Short-acting GLP-1 agonists, such
as lixisenatide, have more pro-
nounced effects on postprandial
blood sugar.
Longer-acting, once-weekly, or once
-daily agents, like liraglutide, would
*SGLT2 Inhibitors
The sodium-glucose cotransporter2
(SGLT2) inhibitor is a new class of
drugs that excretes glucose in the
kidneys. They are very useful for
lowering blood sugar that is non-
insulin-dependent, and for lowering
blood pressure and reducing
weight.
However, they are not very effective
in patients with renal impairment
(glomerular filtration rate < 45 mL/
min).
It is very important to understand
these drug classes in order to pre-
scribe them to the correct patient
population.
P A G E 4
be effective both in the fasting as
well as in the postprandial state.
Addition of these drugs to basal in-
sulin is very effective for glycemic
control. Examples : liraglu-
tide ,semaglutide .
*DPP-4 Inhibitors
Another new class of drugs called
dipeptidyl peptidase 4 (DPP-4) in-
hibitors. These drugs are part of
incretin system and do not cause
that much hypoglycemia when
taken orally. They are very useful
for patients who need a modest
amount of A1c lowering and in
older patients who are afraid of hy-
poglycemia.
T–Cells create problems in the
pancreatic islets , where insulin is
produced.
The Vaccine works by eliminating
the T-Cells .
Patients with diabetes injected with
the vaccine saw an increase in the
levels of a substance called Tumor
Necrosis Factor , the increase in
level of TNF in the system, de-
stroys the T Cells that are hinder-
ing the Production of Insulin.
The results show that dangerous
T-Cells were gone and some people
even began to secrete Insulin on
their own.
In the United States 1.25 million
people suffer from Type 1 Diabetes
and in Pakistan 7.1 million people
suffer from diabetes annually .
A vaccine used over 100years ago
for Tuberclosis has shown promise
in reversing the disease of Type 1
Diabetes.
The body of a person with Type 1
Diabetes does not produce insulin
due to immune system , destroying
the cells that create insulin,
P A K I S T A N P H A R M A C A R E E R D O O R
IMPORTANT INFORMATION:
New Drug Classes for Diabetes Mean New Options:
Vaccine against Diabetes has been officially Announced:

5. *Urgently required:
Male pharmacist 2-3 yrs experience
in ampoules section.
Fresh female pharmacist for Produc-
tion, Dispensing and QA.
QC analyst 1-2 yrs experience.
Share at
ahmed.idrees_79@yahoo.com
———————————————————-
*Urgent required m/f QA officers
for ipc n docs in Atco labs inter-
sected candidates send CV at
Muhammad.shakir@atcolab.com
———————————————————-
*We are looking for a "Quality
Assurance Officer" Male. He should
have done MSc. Chemistry or
Pharm-D with prior experience of at
least 1-2 years in a similar role in
any National or Multinational
pharmaceutical company.
Individuals who have done intern-
*Maple pharma in korangi industrial
area karachi is looking for Production
planner.kindly send CV at
Pharmpakistan@gmail.com
———————————————————-
*A leading pharmaceutical company
is hiring competent professionals for
Regulatory Affairs department, Ex-
port department at Executive and
AM level. Pharma Experience is es-
sential. pharmpakistan@gmail.com
—————————————————-—
*Urgently require Medical Advisor for
our pharma division based in Kara-
chi. Candidates must have 3-5 years
of Medical advisory role. Interested
candidates may send profile at
aqueelur.rahman@bayer.com. Please
mention position in subject line.
—————————————————-—
* A national company is looking for
"Executive Quality Control" with
relevent experience of 4-5 years.
Candidate should be Pharm-D/
Chemist. Interested candidates send
their resume at
sabina.dsouza01@outlook.com
———————————————————-
*Required TM for Karachi region
A leading pharmaceutical company
is hiring competent professionals
for Territory Manager Karachi (TM),
Marketing Department.
Pharma Experience is Must
Contact. navaid.anwar@yahoo.com
———————————————————-
*Following vacancies are available in Ali
Gohar & Company (pvt.)Ltd.,
1)Warehouse Officer (2yrs exp.)
2)Territory Sales Manager(3yr exp.)
3)Territory Sales Officer (1yr exp.)
4)Junior Product Specialist
(PharmD+MBA,2yrs exp.) to apply email
resume on
naveen.jaffri@aligohar.com
P A G E 5
ships can also apply at
hr@epla-labs.com
or
yusra.tariq@epla-labs.com
with position title in subject line.
Location: SITE Area - Khi
———————————————————-
*A well-reputed client in the Pharma-
ceutical industry is seeking Territory
Managers across Pakistan for their
newly acquired medicinal portfolios.
They require young, energetic
individuals with a couple of years’
experience as Sales Representatives or
freshly graduated Pharm D profes-
sionals. If you are interested, please
send your updated CVs on
sonia.elahi@resourcelinked.com
———————————————————-
*A National pharmaceutical com-
pany located in Port qasim karachi
required following positions on ur-
gent basis.
1. QC Analyst
Experience must be 2 to 3 years
2. Validation officer
Experience: 1-2 years
3. Microbiologist having 2 to 3 years
experience.
4.QA Officer minimum 1 year
experience.
Send your cvs at:
Irfan.ahmed@hiranis.com (Position
must mention in subject line)
———————————————————-
*National Pharmaceutical required
Pharmacist for Dispensing Area
( Male only ) candidate must have
at least 1 year Experience interested
candidate may send resume at
dr.arif@hotmail.com.
*Scilife Pharma require Managment
Trainee for Regulatory Department
based in factory Interested incubent
please share your resume at
shariq.mehmood@scilife.biz.
Freshly passed out candidate can
also apply.
Last date for submission is 10th July
2017.
———————————————————-
P A K I S T A N P H A R M A C A R E E R D O O R
JOBS IN PHARMA:

6. Pakistan Pharma Career Door is a Facebook Social Group
created by Dr.Javeriya Ansari (Pharmacsit) on
1st November, 2014 with an aim to provide;
* Latest information about the ongoing Pharma Research.
*Information about new discoveries and inventions in the
field of Science.
*Links to Download Pharma related Books and Notes .
* Link to apply for the Job opportunities in Pharmaceuti-
cal Industries .
*Any query regarding the pharma jobs / pharma subject
will be answered on group and email.
For your contribution and suggestions kindly email on:
pakpharmacareerdoor@gmail.com
USEFUL APP. :
LINKTO BLOG:
http://pakpharmacareerdoor.blogspot.com/
WEBLINK:
https://www.facebook.com/
groups/PakPharmacareerdoor/
PAKISTAN PHARMA
CAREER DOOR